← 產業報告目錄
Blood Clotting Factors Market, By Product Type (Factors VII, Factor VIII, Factor IX, Factor X, Factor XIII, Von Willebrand Factor, Anti-Inhibitor Coagulant Complex, and Others), By Application (Haemophilia (Haemophilia A and Haemophilia B), Von Willebrand Disease, Surgery, and Other Bleeding Disorders), By Technology (Plasma-derived and Recombinant), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
出版商 Coherent Market Insights出版日期 2026-07-30頁數 257報告編號 CMR-835893db58
授權報價
| Single User Price | $4,500 USD |
| Site License Price | $7,000 USD |
| Enterprisewide Price (Global Site License) | $10,000 USD |
報告摘要
The Blood Clotting Factors Market is estimated to be valued at USD 7.43 Bn in 2026 and is expected to reach USD 13.42 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 8.8% from 2026 to 2033. The market is undergoing a major transformation driven by rising prevalence of hemophilia, increasing diagnosis of inherited bleeding disorders, and growing emphasis on effective prophylactic treatment solutions. Blood clotting factors, including factor VIII, factor IX, von Willebrand factor, prothrombin complex concentrates, and other coagulation proteins, enable patients to manage bleeding episodes efficiently while addressing clotting deficiencies, joint damage prevention, surgical bleeding control, and treatment safety standards. The market includes a wide array of product applications like hemophilia A treatment, hemophilia B therapy, von Willebrand disease management, acquired bleeding disorder treatment, surgical hemostasis, and emergency bleeding control.
Patients and healthcare providers are focusing on longer-lasting therapies and convenient treatment approaches to enhance treatment adherence, ensure sustained factor activity, and maintain quality of life. Advancements in recombinant technology, extended half-life products, and plasma-derived purification are improving treatment performance, especially among pediatric, severe hemophilia, and inhibitor-prone patients. In addition, the growing use of home-based prophylaxis, personalized dosing, and hemophilia treatment centers helps optimize factor administration and patient compliance, thereby improving clinical outcomes and reducing bleeding burden.
Market Dynamics
The market is witnessing momentum owing to the increasing diagnosis of hemophilia, rising adoption of preventive factor replacement therapy, and growing demand for advanced bleeding management products. The market’s growth is largely driven by patients, hospitals, and hematology treatment centers seeking effective coagulation therapies, particularly for hemophilia A, hemophilia B, von Willebrand disease, acquired factor deficiencies, surgical bleeding, and other conditions involving impaired blood clotting. Recombinant formulations, plasma-derived concentrates, extended half-life factors, and inhibitor-management therapies play a central role in product development, thereby helping prevent spontaneous bleeding, protect joints, maintain coagulation levels, and support long-term disease management. The rising focus on early diagnosis, prophylactic care, and comprehensive hemophilia treatment is strengthening demand for blood clotting factors.
The expansion of prophylactic treatment programs is fueling market growth. This is mainly driven by improved access to diagnostic services, increasing awareness of inherited bleeding disorders, and broader use of long-acting factor products designed for different patient groups. Product developments involving recombinant manufacturing, half-life extension technologies, enhanced purification, and improved viral safety help reduce infusion frequency, maintain therapeutic factor levels, and support reliable bleeding prevention.
The rising demand for personalized bleeding control is also propelling the market. Hematologists, hemophilia treatment centers, hospital pharmacists, nurses, caregivers, plasma fractionation companies, and specialty healthcare providers play a crucial role in prescribing and supplying clotting factors. As bleeding disorder care becomes more preventive, the market is expected to benefit from wider treatment access, improved diagnostic coverage, stronger patient-support programs, and the introduction of effective, durable, and clinically differentiated factor therapies.
Key Features of the Study
• This report provides in-depth analysis of the Blood Clotting Factors Market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Blood Clotting Factors Market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Shire Plc, Baxter International Inc., Grifols International SA, Roche AG, Bayer AG, Pfizer Inc., Novo Nordisk A/S, Octapharma AG, Biogen Idec, and Kedrion S.P.A.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The Blood Clotting Factors Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Blood Clotting Factors Market
Market Segmentation
• By Product Type (Revenue, USD Bn, 2021-2033)
o Factor VII
o Factor VIII
o Factor IX
o Factor X
o Factor XIII
o Von Willebrand Factor
o Anti-Inhibitor Coagulant Complex
o Others
• By Application (Revenue, USD Bn, 2021-2033)
o Hemophilia
Hemophilia A
Hemophilia B
o Von Willebrand Disease (VWD)
o Surgery
o Other Bleeding Disorders
• By Technology (Revenue, USD Bn, 2021-2033)
o Plasma-derived
o Recombinant
• By Distribution Channel (Revenue, USD Bn, 2021-2033)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• By Region (Revenue, USD Bn, 2021-2033)
o North America
U.S.
Canada
o Latin America
Brazil
Mexico
Argentina
Rest of Latin America
o Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
South Africa
Central Africa
North Africa
• Key Players Insights
o Shire Plc
o Baxter International Inc.
o Grifols International SA
o Roche AG
o Bayer AG
o Pfizer Inc.
o Novo Nordisk A/S
o Octapharma AG
o Biogen Idec
o Kedrion S.P.A.
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Overview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Product Type
Market Snapshot, By Application
Market Snapshot, By Technology
Market Snapshot, By Distribution Channel
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Product Approval
o Collaboration/Merge/Acquisition
o Regulatory Landscape
o PEST Analysis
o Porter’s Five Forces Analysis
o Epidemiology
o Robust Pipeline Analysis
4. Global Blood Clotting Factors Market, By Product Type, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Factor VII
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Factor VIII
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Factor IX
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Factor X
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Factor XIII
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Von Willebrand Factor
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Anti-Inhibitor Coagulant Complex
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
5. Global Blood Clotting Factors Market, By Application, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Hemophilia
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Segment Trends
o Hemophilia A
o Hemophilia B
o Von Willebrand Disease (VWD)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Surgery
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Other Bleeding Disorders
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
6. Global Blood Clotting Factors Market, By Technology, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Plasma-derived
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Recombinant
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
7. Global Blood Clotting Factors Market, By Distribution Channel, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
8. Global Blood Clotting Factors Market, By Region, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2022–2033
Regional Trends
o North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o GCC
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 – 2033, (USD Billion)
o North Africa
o Central Africa
o South Africa
9. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profile
Shire Plc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Baxter International Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Grifols International SA
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Roche AG
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Bayer AG
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Pfizer Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Novo Nordisk A/S
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Octapharma AG
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Biogen Idec
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Kedrion S.P.A.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Analyst Views
10. Section
o References
o Research Methodology
o About Us
圖表清單 List of Tables & Figures
NA
NA
提及公司
o Shire Plco Baxter International Inc.o Grifols International SAo Roche AGo Bayer AGo Pfizer Inc.o Novo Nordisk A/So Octapharma AGo Biogen Ideco Kedrion S.P.A.
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們